Topical Minoxidil and Sexual Function: What the Clinical Evidence Actually Shows

At a glance

  • Drug / minoxidil 5% topical solution or foam, over the counter [5]
  • Labeled use / hair regrowth on the top of the scalp [1][2]
  • Trial side effects reported / itching, scalp irritation, unwanted hair growth [3][4]
  • Men's 5% solution / 1 mL twice daily, men only [1]
  • Women's 5% foam / half a capful once daily [2]
  • Oral tablets / approved for severe hypertension, not hair growth [6]

Does topical minoxidil 5% affect sexual function?

The trial abstracts for topical minoxidil report hair counts, patient and investigator ratings and local skin effects, and none reports libido, erections or other sexual outcomes [3][4][7]. The men's and women's labels list scalp irritation, unwanted facial hair growth, chest pain, rapid heartbeat, faintness, dizziness, weight gain and swelling, and name no sexual effects [1][2].

Oral minoxidil tablets are a different product: a direct-acting peripheral arteriolar vasodilator approved for severe hypertension [6]. Topical minoxidil 2% and 5% are over-the-counter hair regrowth products [5], and the men's 5% solution is labeled for the top of the scalp only, not for frontal baldness or a receding hairline [1].

What the trials measured

In men, 393 participants aged 18 to 49 applied 5% solution, 2% solution or placebo twice daily for 48 weeks; the 5% solution was superior to both comparators for change in nonvellus hair count, with more itching and local irritation on 5% [3].

In women, 381 participants aged 18 to 49 were randomized the same way for 48 weeks; 5% was superior to placebo on all three primary measures, and itching, irritation and hypertrichosis were more frequent with 5% [4].

A third trial tested 5% foam against placebo in 352 men over 16 weeks and found higher hair counts with the foam (P<.0001), along with a better subjective assessment of the hair-loss condition [7]. Hair counts and scalp-coverage ratings were measured in the two solution trials; the foam trial measured hair counts and participants' subjective assessment [3][4][7].

What the labels list

The men's 5% solution label lists 1 mL applied twice daily to the scalp in the hair-loss area and specifies that the product is for men [1]. The women's 5% foam label lists half a capful once daily, with results that may appear at 3 months and may take 6 months [2]. Both labels list heart disease as something to ask a doctor about before use, and list chest pain, rapid heartbeat, faintness, dizziness, sudden unexplained weight gain, swelling of the hands or feet, scalp irritation or redness, and unwanted facial hair growth as reasons to stop use [1][2].

Oral minoxidil is a different exposure

Minoxidil tablets are approved for severe hypertension, and the tablet label says use of minoxidil to promote hair growth is not an approved indication [6]. In a retrospective study of 1404 patients treated with low-dose oral minoxidil for at least 3 months, hypertrichosis occurred in 15.1%, lightheadedness in 1.7%, fluid retention in 1.3% and tachycardia in 0.9% [8]. A 2025 meta-analysis of uncontrolled studies of regimens of 5 mg per day or less found no significant change in systolic or diastolic blood pressure but a heart rate increase of 2.67 beats per minute (95% CI 0.34 to 5.01) [9]. At antihypertensive doses of the tablets, the label describes excess hair growth as occurring without an endocrine abnormality [6].

Frequently asked questions

Can topical minoxidil cause erectile dysfunction?
The Drug Facts warnings for the 5% solution and the 5% foam list scalp irritation, unwanted facial hair growth, chest pain, rapid heartbeat, faintness, dizziness and swelling, and name no sexual effects [1][2]. The efficacy trial abstracts report hair counts and scalp ratings, not sexual outcomes [3][4].
Does topical minoxidil change testosterone?
The topical trial abstracts report hair counts, ratings and skin effects, not hormone levels [3][4].
Does the 5% strength cause more side effects than 2%?
In men, 5% beat 2% on hair count over 48 weeks, with more itching and local irritation [3]. In women, 5% produced more itching, irritation and hypertrichosis than 2% or placebo [4].
I am a woman. Can I use the 5% solution?
The 5% solution label states the product is for men only and says not to use it if you are a woman [1]. The 5% product labeled for women is the foam, half a capful once daily, with results that may take 3 to 6 months [2].

References

  1. U.S. National Library of Medicine, DailyMed. Men's Rogaine Extra Strength minoxidil 5% topical solution, Kenvue prescribing information. Men's Rogaine Extra Strength minoxidil 5% topical solution, Kenvue label
  2. U.S. National Library of Medicine, DailyMed. Women's Rogaine minoxidil 5% topical foam, Kenvue prescribing information. Women's Rogaine minoxidil 5% topical foam, Kenvue label
  3. Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-85. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men
  4. Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541-53. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss
  5. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
  6. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
  7. Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767-74. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men
  8. Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, Moreno-Arrones ÓM, Saceda-Corralo D, Rodrigues-Barata R, et al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients
  9. Chen M, Weichert M, Guo W, Ruzic R, Briley J. Low-dose oral minoxidil does not significantly affect blood pressure: A systematic review and meta-analysis. J Am Acad Dermatol. 2025;92(3):554-555. Low-dose oral minoxidil does not significantly affect blood pressure: A systematic review and meta-analysis
Evidence overview for Topical Minoxidil and Sexual Function: What the Clinical Evidence Actually Shows